TORONTO, Dec. 26, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX: ASP; OTCQB: ASPCF) today announced that Mr. Scott Leckie has resigned from the board of directors of the Company, effective immediately.
About Acerus
Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health.
Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.
Company Contact
Naveed Manzoor
Chief Financial Officer
ir@aceruspharma.com
Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…
Juno Health Rated Highest Overall in Key "Future-Ready" Measures for Small and Rural Hospitals; RHT…
NAPLES, FL / ACCESS Newswire / February 3, 2026 / Stemtech Corporation, the global leader…
Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into…
ESTERO, FL / ACCESS Newswire / February 3, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP)…
Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American…